Martin Taylor
InvestorSenior Associate at F-Prime Capital · Board director at Antlia Bioscience, Inc.
London
Writes $100K – $10M checks · typically $5M
About
Martin Taylor is a Principal at F-Prime Capital focused on company building and early-stage venture capital investment in biotechnology. He has served on the founding or operational teams of five portfolio companies and holds particular interest in oncology, cardiovascular, renal, metabolic, and rare disease therapeutics. He holds a First Class BA and MSci from the University of Cambridge and a PhD from the Cancer Research UK London Research Institute and UCL, with an academic background in molecular biology, biochemistry, biophysics, and genetics.
Contact· self-published, not guessed
Board director at Antlia Bioscience, Inc.
Intro paths
→
In turn, Martin can intro founders to Antlia Bioscience, Inc.'s investors below.
Antlia Bioscience, Inc.'s investors · 1
Experience
- F-Prime CapitalPrincipalcurrent2019 — presentBoston, Massachusetts, United States
- Stealth rare disease companyBoard Directorcurrent2026 — present
- Stealth CV disease companyBoard Directorcurrent2025 — present
- Stealth CV disease companyBoard Observer2023 — 2025
- ImmutrinBoard Observercurrent2026 — present
- Stealth neuro companyBoard Observercurrent2025 — present
- ARTBIOBoard Observercurrent2021 — present
- ARTBIOMember of the founding team (Founding Interim COO)2021 — 2022
- CHARM TherapeuticsMember of founding teamcurrent2021 — present
- CHARM TherapeuticsBoard Observercurrent2021 — present
- AviadoBioBoard Observer2021 — 2026
- Tenpoint Therapeutics LtdBoard Observer2020 — 2024
- Tenpoint Therapeutics LtdMember of the founding team2020 — 2021
- SubIntroBoard Observer2021 — 2022
- MRC Laboratory of Molecular Biology (LMB)Research Scientist (Wellcome Trust Sir Henry Wellcome Postdoctoral Fellow)2016 — 2019Greater Cambridge Area
- Stanford University School of MedicineResearch Scientist2015 — 2016San Francisco Bay Area
- The Francis Crick InstituteResearch Scientist (Scientific Officer)2015London Area, United Kingdom
- Cancer Research UKResearch Scientist (Graduate student / Scientific Officer)2010 — 2015Clare Hall laboratories, London Research Institute
- Medical Research CouncilMRC Summer Student2009Laboratory of Molecular Biology, Cambridge
- Wellcome Trust / Cancer Research UK Gurdon InstituteBBSRC Vacation student2008Cambridge
Skills & more
Biochemistry13Genetics11Cell Culture7Molecular Biology9Cell Biology8Molecular Cloning6Protein Purification5Confocal Microscopy3Cancer Research4Microscopy2Biophysics1C. elegans1
+6 more
Mammalian Cell CultureHigh-Performance Liquid Chromatography (HPLC)Life SciencesCancerScienceFlow CytometryLanguages English · German
From Martin's professional profile.
Deals · 1
Antlia Bioscience, Inc.Board seat
via F-Prime Capital · filed Jun 2026 · $20M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at F-Prime Capital
Abby Wagner
Senior Accountant at F-Prime Capital Partners
Abdul Abdirahman
Principal at F-Prime Capital Partners
Alex Pasteur
Partner at F-Prime Capital Partners
Alex Wong
Associate at F-Prime Capital Partners
Allan Galper
Vice President & Associate General Counsel at F-Prime Capital Partners
Allison MacLeod
Venture Partner at F-Prime Capital Partners
Amber Cai
Venture Partner at F-Prime Capital Partners
Andrew Bognanni
Director of Finance at F-Prime Capital Partners
Frequently asked questions
- Who is Martin Taylor?
- Martin Taylor is a Principal at F-Prime Capital focused on company building and early-stage venture capital investment in biotechnology. He has served on the founding or operational teams of five portfolio companies and holds particular interest in oncology, cardiovascular, renal, metabolic, and rare disease therapeutics. He holds a First Class BA and MSci from the University of Cambridge and a PhD from the Cancer Research UK London Research Institute and UCL, with an academic background in molecular biology, biochemistry, biophysics, and genetics.
- Where does Martin Taylor work?
- Martin Taylor is Senior Associate at F-Prime Capital and Board director at Antlia Bioscience, Inc..
- What check size does Martin Taylor write?
- Martin Taylor typically writes checks of $100K – $10M.
- What boards does Martin Taylor sit on?
- Martin Taylor holds tracked board seats at Antlia Bioscience, Inc..
- Where did Martin Taylor go to school?
- Martin Taylor studied at University of Cambridge (Master’s Degree, Natural Sciences); UCL (Doctor of Philosophy (Ph.D.), Molecular Biology); University of Cambridge (Bachelor’s Degree, Natural Sciences).
Same school
Also attended University of Cambridge894
Stewart ButterfieldCo-founder of Slack and FlickrDemis HassabisCo-founder & CEO of Google DeepMindNiko BonatsosVerdict Capital founder and pre-consensus investor formerly at General CatalystGeorgia StevensonInvestor at Index VenturesHannah SealInvestor at Index VenturesLeah von SiemensPartner at Manta Ray Ventures
.png)
+ 888 more
Shared employers
Also worked at Immutrin3
Also worked at MRC Laboratory of Molecular Biology (LMB)4
Also worked at Stanford University School of Medicine125
Josephine ChenInvestor at Sequoia CapitalJeffrey FinerVenture Partner at Third Rock VenturesFrancisco GimenezInvestment Team at 8VCLan JiangPartner at Lux CapitalJeffrey DeFlavio, MDEntrepreneur in Residence at AlleyCorpLily RaakaStrategist at Plum Alley Investments
+ 119 more
Also worked at The Francis Crick Institute11
Francesco MonacaInvestor at Giant Ventures Global LlpIsabel ZhangInvestor at HCVCOlivier TakJunior Partner at Curie CapitalDr. Rabia KhanAdvisor at The First ThirtyFabio PucciPartner at Arkin CapitalMoustafaSenior Associate, Systems Design at Deep Science Ventures
+ 5 more